Skip to content
The Policy VaultThe Policy Vault

Synarel (nafarelin acetate) — Point32Health

central precocious puberty (CPP)

Initial criteria

  • Patient age < 12 years
  • Documented diagnosis of central precocious puberty (CPP)

Approval duration

through age 18 years